Plasma levels of soluble intercellular adhesion molecule-1 as a biomarker for disease severity of patients with community-acquired pneumonia

Pin Yu Chang, Shih Ming Tsao, Jer Hwa Chang, Ming-Hsien Chien, Wen Yueh Hung, Yi Wen Huang, Shun Fa Yang

研究成果: 雜誌貢獻文章

2 引文 (Scopus)

摘要

Background Community-acquired pneumonia (CAP) is characterized as an acute inflammation of the lung associated with the activation of macrophages and neutrophils. Intercellular adhesion molecule-1 (ICAM-1) is an essential adhesion molecule involved in immune cell recruitment in lung inflammation. We investigated whether ICAM-1 is a useful biomarker for assessing the disease severity of hospitalized adult patients with CAP. Methods Plasma soluble ICAM-1 (sICAM-1) levels were measured in 78 patients with CAP and 69 healthy controls by using a commercial enzyme-linked immunosorbent assay. The pneumonia severity index scores were used to determine CAP severity in patients upon initial hospitalization. Results The sICAM-1 and C-reactive protein (CRP) levels decreased significantly in patients with CAP after antibiotic treatment. The plasma concentration of sICAM-1 alone, but not CRP, was correlated with CAP severity according to the pneumonia severity index scores (r = 0.431, p < 0.001). The sICAM-1 levels in patients with CAP with high mortality risk were significantly higher than those in patients with CAP with medium or low mortality risk. Moreover, the sICAM-1 level showed a significant correlation with the length of hospital stay (r = 0.488, p < 0.001). Mechanistic investigations found that bacterial lipopolysaccharide induced upregulation of ICAM-1 expression through the c-Jun N-terminal kinase pathway in RAW264.7 macrophages. Conclusions Plasma sICAM-1 levels may play a role in the diagnosis and clinical assessment of CAP severity.
原文英語
頁(從 - 到)174-180
頁數7
期刊Clinica Chimica Acta
463
DOIs
出版狀態已發佈 - 十二月 1 2016

指紋

Biomarkers
Intercellular Adhesion Molecule-1
Pneumonia
Plasmas
Macrophages
C-Reactive Protein
Immunosorbents
Length of Stay
JNK Mitogen-Activated Protein Kinases
Lipopolysaccharides
Neutrophil Activation
Assays
Macrophage Activation
Mortality
Adhesion
Chemical activation
Anti-Bacterial Agents
Molecules
Hospitalization
Up-Regulation

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

引用此文

Plasma levels of soluble intercellular adhesion molecule-1 as a biomarker for disease severity of patients with community-acquired pneumonia. / Chang, Pin Yu; Tsao, Shih Ming; Chang, Jer Hwa; Chien, Ming-Hsien; Hung, Wen Yueh; Huang, Yi Wen; Yang, Shun Fa.

於: Clinica Chimica Acta, 卷 463, 01.12.2016, p. 174-180.

研究成果: 雜誌貢獻文章

@article{938d06f3228b4b91a40c81a3bc8f6625,
title = "Plasma levels of soluble intercellular adhesion molecule-1 as a biomarker for disease severity of patients with community-acquired pneumonia",
abstract = "Background Community-acquired pneumonia (CAP) is characterized as an acute inflammation of the lung associated with the activation of macrophages and neutrophils. Intercellular adhesion molecule-1 (ICAM-1) is an essential adhesion molecule involved in immune cell recruitment in lung inflammation. We investigated whether ICAM-1 is a useful biomarker for assessing the disease severity of hospitalized adult patients with CAP. Methods Plasma soluble ICAM-1 (sICAM-1) levels were measured in 78 patients with CAP and 69 healthy controls by using a commercial enzyme-linked immunosorbent assay. The pneumonia severity index scores were used to determine CAP severity in patients upon initial hospitalization. Results The sICAM-1 and C-reactive protein (CRP) levels decreased significantly in patients with CAP after antibiotic treatment. The plasma concentration of sICAM-1 alone, but not CRP, was correlated with CAP severity according to the pneumonia severity index scores (r = 0.431, p < 0.001). The sICAM-1 levels in patients with CAP with high mortality risk were significantly higher than those in patients with CAP with medium or low mortality risk. Moreover, the sICAM-1 level showed a significant correlation with the length of hospital stay (r = 0.488, p < 0.001). Mechanistic investigations found that bacterial lipopolysaccharide induced upregulation of ICAM-1 expression through the c-Jun N-terminal kinase pathway in RAW264.7 macrophages. Conclusions Plasma sICAM-1 levels may play a role in the diagnosis and clinical assessment of CAP severity.",
keywords = "Community-acquired pneumonia, ICAM-1, JNK pathway, LPS",
author = "Chang, {Pin Yu} and Tsao, {Shih Ming} and Chang, {Jer Hwa} and Ming-Hsien Chien and Hung, {Wen Yueh} and Huang, {Yi Wen} and Yang, {Shun Fa}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.cca.2016.10.030",
language = "English",
volume = "463",
pages = "174--180",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Plasma levels of soluble intercellular adhesion molecule-1 as a biomarker for disease severity of patients with community-acquired pneumonia

AU - Chang, Pin Yu

AU - Tsao, Shih Ming

AU - Chang, Jer Hwa

AU - Chien, Ming-Hsien

AU - Hung, Wen Yueh

AU - Huang, Yi Wen

AU - Yang, Shun Fa

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background Community-acquired pneumonia (CAP) is characterized as an acute inflammation of the lung associated with the activation of macrophages and neutrophils. Intercellular adhesion molecule-1 (ICAM-1) is an essential adhesion molecule involved in immune cell recruitment in lung inflammation. We investigated whether ICAM-1 is a useful biomarker for assessing the disease severity of hospitalized adult patients with CAP. Methods Plasma soluble ICAM-1 (sICAM-1) levels were measured in 78 patients with CAP and 69 healthy controls by using a commercial enzyme-linked immunosorbent assay. The pneumonia severity index scores were used to determine CAP severity in patients upon initial hospitalization. Results The sICAM-1 and C-reactive protein (CRP) levels decreased significantly in patients with CAP after antibiotic treatment. The plasma concentration of sICAM-1 alone, but not CRP, was correlated with CAP severity according to the pneumonia severity index scores (r = 0.431, p < 0.001). The sICAM-1 levels in patients with CAP with high mortality risk were significantly higher than those in patients with CAP with medium or low mortality risk. Moreover, the sICAM-1 level showed a significant correlation with the length of hospital stay (r = 0.488, p < 0.001). Mechanistic investigations found that bacterial lipopolysaccharide induced upregulation of ICAM-1 expression through the c-Jun N-terminal kinase pathway in RAW264.7 macrophages. Conclusions Plasma sICAM-1 levels may play a role in the diagnosis and clinical assessment of CAP severity.

AB - Background Community-acquired pneumonia (CAP) is characterized as an acute inflammation of the lung associated with the activation of macrophages and neutrophils. Intercellular adhesion molecule-1 (ICAM-1) is an essential adhesion molecule involved in immune cell recruitment in lung inflammation. We investigated whether ICAM-1 is a useful biomarker for assessing the disease severity of hospitalized adult patients with CAP. Methods Plasma soluble ICAM-1 (sICAM-1) levels were measured in 78 patients with CAP and 69 healthy controls by using a commercial enzyme-linked immunosorbent assay. The pneumonia severity index scores were used to determine CAP severity in patients upon initial hospitalization. Results The sICAM-1 and C-reactive protein (CRP) levels decreased significantly in patients with CAP after antibiotic treatment. The plasma concentration of sICAM-1 alone, but not CRP, was correlated with CAP severity according to the pneumonia severity index scores (r = 0.431, p < 0.001). The sICAM-1 levels in patients with CAP with high mortality risk were significantly higher than those in patients with CAP with medium or low mortality risk. Moreover, the sICAM-1 level showed a significant correlation with the length of hospital stay (r = 0.488, p < 0.001). Mechanistic investigations found that bacterial lipopolysaccharide induced upregulation of ICAM-1 expression through the c-Jun N-terminal kinase pathway in RAW264.7 macrophages. Conclusions Plasma sICAM-1 levels may play a role in the diagnosis and clinical assessment of CAP severity.

KW - Community-acquired pneumonia

KW - ICAM-1

KW - JNK pathway

KW - LPS

UR - http://www.scopus.com/inward/record.url?scp=84993982813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993982813&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2016.10.030

DO - 10.1016/j.cca.2016.10.030

M3 - Article

C2 - 27983998

AN - SCOPUS:84993982813

VL - 463

SP - 174

EP - 180

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -